|
Overview
Back-to-Back with Validation and Results from Virtual Screening:
Computational
Strategies for Smarter Discovery and Development,
June 30 - July 1, 2004
|
Overview |
Biology has considerable experience with gene and protein-centered informatics,
but chemistry is at an earlier stage of developing databases that are truly
compound-centric. The historical paradigm of identifying and optimizing hits for
potency, and then looking to evaluate and optimize for ADME and toxicity
properties is quickly shifting to a more parallel approach that considers ADME/Tox
properties at an earlier stage. This concept is epitomized by methods for
differentiating between drug-like and non-drug-like compounds, the use of which
is increasing significantly.
Moving compound profiling earlier means that many more compounds must be
assessed, which is both the value and the challenge of this shift. Early
determination of properties for many compounds requires the use of computational
or high throughput surrogate methods. Prioritizing compounds using such data,
however, should provide significant competitive advantage by dramatically
improving quality and success rates for further development. Innovative
strategies, potential pitfalls and issues requiring further advances will be
highlighted, along with the practical experience of first movers in this field.
Scientific Advisors:
Dr. Mark Murcko, Vertex Pharmaceuticals, Inc.
Dr. Chris Lipinski, Pfizer
Dr. Keith Russel, AstraZeneca Pharmaceuticals |
|
|
Compound-Centric Information |
Dr. Phil Edwards, AstraZeneca
Dr. Mark Murcko, Vertex Pharmaceuticals, Inc.
Dr. Paul Clemons, Harvard University
Dr. Felix Frueh, TheraSTrat AG
|
|
Compound Efficacy and Selectivity |
Dr Timothy Perera, Johnson & Johnson PRD
Dr. Holger Hiemisch, Axaron Bioscience AG
Dr. David Bol, Avalon Pharmaceuticals, Inc.
Dr. Yan Luo, Abbott Laboratories
Dr. Petra Ross-Macdonald, Bristol-Myers Squibb
Dr. Bert Pronk, Serenex
|
|
Profiling for ADME/Tox |
Dr. Terry Stouch, Lexicon Pharmaceuticals
Dr. Adam Gilbert, Wyeth Research
Dr. Jonathan S. Mason, Pfizer Global R&D
|
|
Drug-like and Lead-like Properties and Filters |
Dr. Tudor Oprea, University of New Mexico
Dr. Zhengming Chen, Purdue Pharma
Dr. Gilbert Rishton, Amgen, Inc.
Dr. Michal Vieth, Lilly Research Laboratories
Dr. Ajay, Celera
|
Call for Exhibitors and Sponsors
Showcase your company's expertise, brand your solutions and develop revenue
opportunities with qualified decision-makers by becoming an Exhibitor or Sponsor
of these exciting conferences! I will gladly work with you in customizing a
solution to meet your specific marketing goals and budgets.
For exhibit and sponsorship information, please contact
Angela Parsons at 781-972-5467 or
aparsons@healthtech.com
|
